Published in Lancet on May 27, 2000
Corellation of Mutations, TILs and Age in Breast Cancer | NCT04033965
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Breast cancer before age 40 years. Semin Oncol (2009) 2.71
An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat (2007) 2.65
Breast cancer in young women: poor survival despite intensive treatment. PLoS One (2009) 2.36
Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer (2009) 1.89
Conditional survival among cancer patients in the United States. Oncologist (2010) 1.51
Breast cancer in young women in a limited-resource environment. World J Surg (2010) 1.48
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
Breast cancer in young women and its impact on reproductive function. Hum Reprod Update (2009) 1.40
Breast cancer in young women. Breast Cancer Res (2010) 1.31
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer (2002) 1.17
Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS One (2013) 1.07
Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. Br J Cancer (2012) 1.06
Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer (2008) 0.97
Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg (2011) 0.97
Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer (2009) 0.96
Modeling the effect of age in T1-2 breast cancer using the SEER database. BMC Cancer (2005) 0.95
Hormonal therapies in young breast cancer patients: when, what and for how long? J Thorac Dis (2013) 0.94
Unique features of young age breast cancer and its management. J Breast Cancer (2014) 0.89
Benefits and adverse effects of endocrine therapy. Ann Oncol (2010) 0.88
Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient. J Cancer Res Clin Oncol (2006) 0.87
GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients. Breast Cancer Res (2007) 0.86
Tumor Invasiveness, Not Lymphangiogenesis, Is Correlated with Lymph Node Metastasis and Unfavorable Prognosis in Young Breast Cancer Patients (≤35 Years). PLoS One (2015) 0.84
Adjuvant Endocrine Therapy in Premenopausal Patients. Breast Care (Basel) (2008) 0.84
Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study. Breast Cancer Res (2006) 0.84
Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys (2007) 0.83
Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. Breast Cancer Res (2007) 0.83
Breast carcinoma in young patients. Lancet (2000) 0.82
Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PLoS One (2014) 0.82
Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer. BMC Cancer (2012) 0.81
Clinical Significance of Age at the Time of Diagnosis among Young Breast Cancer Patients. J Breast Cancer (2011) 0.80
Breast cancer in 30-year-old or younger patients: clinicopathologic characteristics and prognosis. World J Surg Oncol (2015) 0.80
Prognostic effect analysis of molecular subtype on young breast cancer patients. Chin J Cancer Res (2015) 0.79
The prognostic value of age for invasive lobular breast cancer depending on estrogen receptor and progesterone receptor-defined subtypes: A NCDB analysis. Oncotarget (2016) 0.79
Breast cancer in moroccan young women: a retrospective study. BMC Res Notes (2010) 0.79
Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment. Breast Cancer Res (2009) 0.78
Age of 40 years or younger is an independent risk factor for locoregional failure in early breast cancer: a single-institutional analysis in saudi arabia. J Oncol (2012) 0.78
Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. Breast Cancer Res Treat (2016) 0.78
The pattern of prognostic and risk indicators among women with breast cancer undergoing modified radical mastectomy in Dar es Salaam, Tanzania. Infect Agent Cancer (2016) 0.78
An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ⩽40 years at breast cancer diagnosis. Br J Cancer (2015) 0.77
Fertility preservation in reproductive-age women facing gonadotoxic treatments. Curr Oncol (2015) 0.77
Breast carcinoma in young patients. Lancet (2000) 0.77
Younger patients have poorer biochemical outcome after radical prostatectomy in high-risk prostate cancer. Asian J Androl (2011) 0.76
Prognostic and Predictive Markers for Treatment Decisions in Early Breast Cancer. Breast Care (Basel) (2011) 0.76
Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Res Treat (2016) 0.75
Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer. PLoS One (2016) 0.75
Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women. Br J Cancer (2001) 0.75
Temporal trend, clinicopathologic and sociodemographic characterization of age at diagnosis of breast cancer among US women diagnosed from 1990 to 2009. Springerplus (2014) 0.75
Treatment of breast cancer in young women: do we need more aggressive therapies? J Thorac Dis (2013) 0.75
Retrospective analysis of breast cancer prognosis among young and older women in a Brazilian cohort of 738 patients, 1985-2002. Oncol Lett (2016) 0.75
False negatives in oestrogen-receptor assay. Lancet (2000) 0.75
A small cosmid for efficient cloning of large DNA fragments. Gene (1980) 22.61
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Cosmids: a type of plasmid gene-cloning vector that is packageable in vitro in bacteriophage lambda heads. Proc Natl Acad Sci U S A (1978) 16.33
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
Use of alternative medicine by women with early-stage breast cancer. N Engl J Med (1999) 7.37
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (2007) 7.33
Analysis of survival by tumor response. J Clin Oncol (1983) 5.91
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol (2001) 5.31
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 5.22
Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst (1997) 4.60
School-based programs to reduce sexual risk behaviors: a review of effectiveness. Public Health Rep (1994) 4.50
Redressing the balance--the ethics of not entering an eligible patient on a randomised clinical trial. Ann Oncol (1992) 4.41
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med (1995) 4.03
Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol (1996) 4.02
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93
Plasmids useable as gene-cloning vectors in an in vitro packaging by coliphage lambda: "cosmids". Gene (1978) 3.66
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
Cloning of the complete human cytomegalovirus genome in cosmids. Gene (1982) 3.55
Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J (Clin Res Ed) (1986) 3.52
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst (1998) 3.50
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet (1999) 3.50
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol (2000) 3.33
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science (1995) 3.25
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood (2001) 3.24
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Activation of a transposable element in the germ line but not the soma of Caenorhabditis elegans. Nature (1987) 3.00
Gonadotrophin stimulation test ovarian function. Br Med J (1968) 2.99
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
Organization and function of an accident flying squad. Br Med J (1966) 2.88
The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer (1997) 2.75
Instability of palindromic DNA in Escherichia coli. Cold Spring Harb Symp Quant Biol (1981) 2.75
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
Escherichia coli plasmids packageable in vitro in lambda bacteriophage particles. Methods Enzymol (1979) 2.71
Fertility and ageing. Hum Reprod Update (2005) 2.68
Changing character of cervical cancer in young women. BMJ (1989) 2.66
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol (2001) 2.59
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer (2001) 2.58
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol (1989) 2.57
Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol (2001) 2.37
Sequence interruptions in enterobacterial repeated elements retain their ability to encode well-folded RNA secondary structures. Mol Microbiol (1997) 2.33
Free ribosomal DNA molecules from Tetrahymena pyriformis GL are giant palindromes. J Mol Biol (1976) 2.33
Who gets chemotherapy for metastatic lung cancer? Chest (2000) 2.27
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol (2008) 2.26
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Precise and nearly-precise excision of the symmetrical inverted repeats of Tn5; common features of recA-independent deletion events in Escherichia coli. Gene (1983) 2.21
Molecular definition of the 22q11 deletions in velo-cardio-facial syndrome. Am J Hum Genet (1995) 2.19
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med (2000) 2.17